Introduction

Endoscopic papillectomy(EP)is a viable treatment option for ampullary lesions(AL).While many studies have reported low morbidity and acceptable outcomes, early attempts to pool data from these initial experiences have produced conflicting conclusions regarding key technical aspects. To address these uncertainties, we conducted a systematic review and pooled analysis to evaluate the safety and efficacy of EP for AL,identifying factors that may influence outcomes.

Aims & Methods

Electronic databases(Medline, Scopus and EMBASE)were searched up to September 2024. Studies that included patients with endoscopically resected AL were eligible. Efficacy and safety outcomes were pooled by means of a random-effects model to obtain a proportion with a 95% confidence interval(CI). Univariable meta-regression analyses were conducted to explore potential factors affecting outcomes.

Results

A total of 60 studies(4,859 lesions)published between 2002 and 2024 were analyzed. Complete resection was achieved in 86.2%of cases, though intraductal involvement limited success. The recurrence rate was 18.6%, however, the majority(89.3%)of patients were managed endoscopically without surgery. The pooled adverse event(AE)rate was 30.0%, with bleeding(12.2%)and post-procedural pancreatitis(11.1%)being the most common complications. Prophylactic stenting reduced pancreatitis risk, while intraductal involvement increased perforation risk.Adjunctive treatments for intraductal involvement were associated with an increased risk of papillary stricture.

Conclusion

Endoscopic papillectomy is a safe and effective treatment for ampullary lesions. However, lesions with intraductal extension pose a higher risk of incomplete resection and perforation, warranting careful evaluation of the benefit-risk balance in these cases. While prophylactic pancreatic stenting may reduce the incidence of post-procedural pancreatitis, optimizing strategies to minimize overall adverse events remains a key focus for future research.

Introduction

The Tokyo Guidelines recommend a CRP cutoff >10 mg/L for diagnosing acute cholangitis. However, this threshold was defined in lithiasic populations and may not be applicable to malignant biliary obstruction, where CRP elevation often reflects tumor-driven inflammation rather than true infection. Applying this universal threshold in oncologic settings risks antibiotic overuse and promotes resistance.

Aims & Methods

This study aimed to reassess the diagnostic value of the current CRP cutoff in tumor-related cholangitis and to identify a more appropriate threshold to enhance specificity and guide targeted antibiotic use.
We conducted a retrospective monocentric study of consecutive patients at a tertiary center between May 2016 and October 2024. Among 571 patients undergoing ERCP, 268 patients with confirmed malignant biliary obstruction and available bile sampling were included. Bacteriological status was defined as positive when either direct bile examination or culture isolated microorganisms. CRP levels, leukocyte counts (hyperleukocytosis >10,000/mm³), and tumor etiology were recorded. ROC curve analysis was performed to determine the optimal CRP cutoff. Comparative analyses employed Mann-Whitney U, chi-square, and multivariate logistic regression.

Results

The mean age was 65.9 ± 12.4 years, with an equal sex distribution (50% male). Tumor etiologies included pancreatic cancer (56%), cholangiocarcinoma (22%) — 40 hilar and 18 distal cases, gallbladder cancer (13%), ampulloma (7%), and extrinsic or secondary compression (3%). The median CRP was significantly higher in culture-positive patients (47 mg/L [IQR 21–98]) compared to culture-sterile patients (22 mg/L [IQR 11–36]; p<0.001). ROC analysis identified an optimal CRP cutoff of 21 mg/L (AUC = 0.64), achieving a sensitivity of 67% and specificity of 54%. Hyperleukocytosis was present in 66% of culture-positive cases versus 31% of sterile cases (p<0.001). In multivariate analysis, CRP ≥21 mg/L (OR 2.1; 95% CI [1.3–3.4]; p=0.002) and hyperleukocytosis (OR 3.4; 95% CI [1.9–5.9]; p<0.001) were independently associated with bile bacteriological positivity.

Conclusion

In malignant biliary obstruction, the universal CRP threshold of 10 mg/L lacks specificity and risks antibiotic overuse. A higher threshold around 21–25 mg/L, combined with leukocyte count assessment, improves diagnostic precision. Our findings advocate for a context-specific adaptation of the Tokyo Guidelines to better differentiate tumor-related inflammation from true infection, ultimately enhancing patient safety and antimicrobial stewardship in oncologic care.

Clinical Case Summary

Introduction: Dieulafoy lesions account for less than 2% of gastrointestinal bleeds, and only 20% of these occur outside the stomach. We present a rare case of a bleeding ampullary Dieulafoy lesion with technical difficulties in management, starting with a standard forward-viewing gastroscope, subsequent use of a side-viewing duodenoscope, and eventually endoscopic retrograde cholangiopancreatography (ERCP) and stenting to allow for safe haemostasis with argon plasma coagulation (APC).
Case report: A 56-year-old male was admitted with pneumonia and fluid overload in the context of end-stage renal disease from poorly controlled diabetes mellitus and hypertensive nephrosclerosis on regular haemodialysis. He was on dual anti-platelet therapy with aspirin and ticagrelor for a recent cardiac stent.
Five days into his admission he was noted to have melena with a haemoglobin drop from 87 g/L to 56 g/L, with a urea rise of 23.9 mmol/L from a baseline of 11.0 mmol/L.
Subsequent gastroscopy revealed active bleeding from the major ampulla without any underlying ulcer or tumour, superior to the biliary orifice, consistent with an ampullary Dieulafoy lesion. The duodenoscope was then introduced for a better view and access to the major ampulla. APC was attempted at 0.8 L/min at 30 Watts due to the size and location, but haemostasis was unsuccessful.
The decision was made to proceed to ERCP and biliary stenting to prevent complications from heat injury to the bile duct and possible pancreatitis. A 7 Fr by 4 cm double pigtail biliary plastic stent was placed into the common bile duct. APC was re-applied at 0.8 L/min at 30 Watts at the bleeding spot with successful haemostasis.
Discussion: This case report aims to highlight the rare occurrence of duodenal ampullary Dieulafoy lesions and the need for prompt recognition and use of resources such as side-view duodenoscopy and ERCP for safe therapeutic management.

Disclosure

None

Introduction

In ulcerative colitis (UC) clinical trials, endoscopic disease activity is commonly assessed via central reading of the overall Mayo Endoscopic Score (MES). Segmental MES can provide a more detailed evaluation of mucosal response, but it is limited by high inter-rater variability in both anatomical landmark localization and disease activity grading. Automatic MES grading can assist reducing reader discrepancies and detect local mucosal changes that may not be estimated by global scoring. In this study, we developed and evaluated an artificial intelligence (AI)-based system for automated segmental MES grading enabling disease extent quantification and granular endoscopic remission estimation.

Aims & Methods

In contrast to previous approaches, the proposed AI system introduces a novel hierarchical framework for automated MES grading at the frame-, segment-, and video-level. The system comprises three modules, trained on 5,897 retrospectively acquired, aggregated, and anonymized endoscopic videos. A foundation model (FM), trained on 22 million frames, was developed to extract clinically relevant frames from full-length colonoscopies. A colon segmentation module was built upon the FM to localize three anatomical segments: descending colon (DC), sigmoid colon (SI), and rectum (RM). An automated MES classification module was then trained to perform frame-level MES grading. Hierarchical aggregation of local scores, combined with temporal smoothing and non-informative filtering, enabled both segmental and global MES estimation. For independent testing, 915 colonoscopy videos were annotated for each segment for MES scoring by expert gastroenterologists using a 2+1 reading paradigm. Colon segment reference annotations were automatically extracted from endoscopic videos based on recording software annotations. System performance was evaluated using the Quadratic Weighted Kappa (QWK) for both segmental and overall MES agreement. Classification accuracy in detecting endoscopic granular remission (MES 0, 1 vs 2, 3) was reported for all colon segments.

Results

The AI system demonstrated strong agreement (QWK=0.752 [95% CI: 0.719, 0.782]) with gastroenterologist assessments for overall MES on the test dataset. Good agreement was confirmed for SI (QWK=0.647 [95% CI: 0.602, 0.687]) and RM (QWK=0.687 [95% CI: 0.646, 0.724]), moderate agreement was found for DC (QWK=0.592 [95% CI: 0.541, 0.638]). Frame-level colon segment classification accuracy was 41% for DC, 69% for SI, and 78% for RM; with lower performance in DC linked to high variability in reference annotations. Colon segmentation enabled a 37.72% reduction in mean colonoscopy video time by filtering out-of-body and insertion-phase sections. The system showed very high accuracy in detecting both overall (ACC=90.38%) and segmental (DC: 78.80%; SI: 82.84%; RM: 85.03%) endoscopic remission. Mean accuracy in detecting the number of colon segments per video with active disease was 59.13%.

Conclusion

We introduced a novel AI system for automated, granular MES scoring in ulcerative colitis patients, hierarchically grading colonoscopy videos. Our framework demonstrated strong agreement with gastroenterologists in both overall and segmental endoscopic activity assessments. By integrating continuous scoring with anatomical landmarking, the AI system can offer a more comprehensive view of total disease burden in UC patients which can lead to improved precision of disease estimation and treatment response evaluation in clinical settings.

Disclosure

All authors are employees of Clario Inc., Philadelphia, USA.

Introduction

The Tokyo Guideline 2018 recommends laparoscopic cholecystectomy as the gold standard therapy for acute cholecystitis regardless of the severity and the onset of symptoms, as long as the patient is fit for surgery. Approximately 20% of the patients undergo acute cholecystectomy in our region, and in the remainder of the patients, we have to take into consideration the likelihood of recurrent inflammation after the regression with conservative therapy. According to the TG 2018, the drainage of the gallbladder is recommended in grade II and grade III cholecystitis. This can be carried out by interventional radiologist as percutaneous transhepatic gallbladder drainage (PTGBD), by endoscopist as transpapillary gallbladder drainage (TPGBD) or endosonography-guided gallbladder drainage (EUS-GBD).

Aims & Methods

The primary endpoint of our prospective, non-randomized, observational study was to determine the technical (successful stent implantation into the gallbladder) and clinical success (repeated need for drainage and absence of recurrent cholecystitis) of TPGBD in those patients that underwent it from 01.01.2023 at the University of Szeged. Our secondary endpoint was the comparison of the time of hospitalization between the patients who underwent clinically successful TPGBD and those who underwent PTGBD for grade II/III cholecystitis.

Results

Altogether 19 patients had undergone TPGBD, 74% of them were female, the average age was 64,53. Previously 21% had cholecystitis, 47% had cholecystolithiasis, while 16% had choledocholithiasis and 11% of the patients gone under PTGBD. TPGBD was carried out because of grade II cholecystitis in 89% of the patients, and grade III in the rest of them. 63% was considered at least a 3 in the ASA physical status classification. Altogether the technical success rate was 58%, a cholangioscop was used in 37% of the cases. The successful canulation rate of the bile duct was 89%, while the canulation rate of the cystic duct was 68%. There were two cases, where after the canulation of the cystic duct the implantation of the plastic stent was not possible. 3 patients were referred for PTGBD after an unsuccessful TPGBD, the remainder patients with an unsuccessful TPGBD received conservative therapy. After a technically successful TPGBD, only one patient went under PTGBD due to his severe comorbidities, rather than a repeated TPGBD. 6 patients underwent cholecystectomy averagely in 8,5 weeks after the TPGBD, the remainder of patients did not have neither the need for repeated drainage nor any symptoms requiring urgent care due to cholelithiasis. Comparing this group with 11, randomly chosen patients who underwent PTGBD for at least grade II cholecystitis during the period of the study, we detected that the time of hospitalization after the drainage was less (8,2 days vs 13,3 days), and less patients required repeated drainage or had recurrent cholecystitis (1 vs 4).

Conclusion

Although TPGBD imposed a great challenge before the use of cholangioscop in everyday practice, nowadays it is becoming an accepted part of the therapeutic algorithm in the treatment of cholecystitis, where an acute cholecystectomy is not performed. Our results suggest that TPGBD can lead to shortened hospitalization and have less complications than TPGBD. Our findings will serve as a basis for a future extension of the study and for the design of a randomised prospective study with a control group.